Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Potential COVID-19 treatment LAM-002A to enter Phase II clinical trial

europeanpharmaceuticalreviewJuly 29, 2020

Tag: COVID-19 , LAM-002A , Yale University , AI Therapeutics

PharmaSources Customer Service